OBJECTIVE： To evaluate the effects of PDCA cycle management on standardizing rational use of ribavirin in children， and to investigate the effectiveness and safety of ribavirin in children. METHODS： By adopting 4 times of PDCA cycle， clinical pharmacists conducted continuous intervention to ribavirin use in pediatric department； authoritative guideline and evidence-based evidence were reviewed； List of Antiviral Therapy Plans in Qutpatient Department of Prediatrics was formulated in our hospital， which provided antiviral therapy plan of common pediatric infectious disease. By compared the rationality of ribavirin prescription in the pre and post PDCA cycle management （intervention group and non-intervention group） to evaluate the effects of standard management. RESULTS & CONCLUSIONS： After 4 times of PDCA cycle， the consumption amount of ribavirin both reduced significantly. The proportion of ribavirin prescriptions decreased from 3.10％ to 0.80％ （P＜0.01）； the proportion of suitable medication indication prescriptions increased from 56.14％ to 90.30％ （P＜0.01）； diagnosed disease types of commonly prescribed ribavirin prescriptions decreased from 26 to 5； the proportion of suitable administration route prescriptions increased from 73.43％ to 93.75％. The proportion of ribavirin combined with antibiotics prescriptions decreased from 59.74％ to 12.91％ （P＜0.01）. PDCA is an effective and feasible method for pediatric medication management by clinical pharmascits. Ribavirin is not recommended as routine antiviral drug for children due to its unclear clinical benefit and distinct toxicity.